NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that 3D cell culturing technology developed by its joint venture partner Nano3D BioSciences (n3D) was recently used in a breakthrough study using stem cells.
Dr. Mikhail Kolonin, an associate professor at the University of Texas Health Science Center at Houston, and Dr. Glauco Souza of n3D authored a study that demonstrates how effective 3D cell culturing by magnetic levitation is in generating white adipose tissue organoids, or adiposphere. In a significant breakthrough, these 3D structures presented vascular-like structures when pre-adpocyte stem cells were co-cultured with endothelial cells.
The study, “Adipose tissue engineering in three-dimensional levitation tissue culture system based on magnetic nanoparticles,” was published in the journal Tissue Engineering C.
“This paper shows just how valuable n3D’s Bio-Assembler can be in ground-breaking research being conducted around the world,” said RBCC CEO Patrick Brown. “As more and more high-profile cell researchers discover this system’s potential, the market for the technology will continue to grow exponentially.”
The Bio-Assembler’s fusion of magnetic levitation and nanoparticle assembly technology allows it to produce accurate, 3D representations of in vivo tissues faster and easier than any other existing tools. The incredible device is key to RBCC’s plans to participate in the impressive upside in store for n3D.
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen, Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.